Alvotech Stock Earnings Reports

Alvotech reported Q1 2026 results and focused the quarter on advancing FDA interactions, completing BLA resubmissions, and scaling global commercial operations. An FDA routine GMP surveillance inspection is underway at the Reykjavik site and the company expects it to close imminently; Alvotech says it has taken extra time to remediate quality findings and will resubmit BLAs for biosimilars to Simponi, Eylea, Prolia and Xgeva, targeting approvals later in 2026 (resubmission process) with commercial upside in 2027. The company announced a strategic manufacturing agreement with Fujifilm Biotechnologies to diversify capacity and add U.S.-based supply starting in H2 2027 (following tech transfer and qualification). Commercially, AVT02 (Humira biosimilar) is cited as the fastest-growing Humira biosimilar in the U.S., achieving ~10% share in its segment and contributing to product revenue; AVT04 (Stelara biosimilar) and newly approved AVT03/AVT05/AVT06 are contributing across markets. Q1 financials: revenues $106M (down 20% YoY), adjusted EBITDA $24M (23% margin), gross margin 57%; product revenues $51M and licensing revenues $55M. Performance was impacted by reduced manufacturing throughput during facility improvements; operations are expected to normalize during Q2. Cash at quarter-end $64M; operating cash flow negative $25M in Q1 due mainly to working capital and continued interest payments. Guidance for full-year 2026: revenues $650M–$700M and adjusted EBITDA $180M–$220M; company expects Q4 2026 to be the strongest quarter and targets positive free cash flow in Q4 2026. Key risks remain regulatory timing, manufacturing normalization, and milestone-dependent (lumpy) licensing revenue recognition.